Company / Current Liabilities
KalVista Pharmaceuticals, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$45.2M
FY2025
5-year range
$9.8M / $45.2M
FY2021-FY2025
Trend
+98.0%
vs FY2024
Sector context
#151 of 213
Health Care
What the data says
At $45M, KalVista Pharmaceuticals, Inc.'s current liabilities ranks #63 of 213 in the Health Care sector. Current Liabilities has increased for 5 consecutive years, from $8M in FY2020 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of +42.4%.
Increased from $15M to $45M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +57.4%
- 5-Year CAGR
- +42.4%
- 10-Year CAGR
- -
Sector benchmark
#63 of 213 in Health CareTop 29% of 213This company $45.2M Sector average $1.6B
▼
-97.2% below sector average
Key checks
Key Insights
- KalVista Pharmaceuticals, Inc.'s current liabilities has grown for 5 consecutive years.
- 5-year CAGR of +42.4%, indicating consistent growth.
- In FY2025, current liabilities increased 98.0% year-over-year.
- Ranks #151 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.2M | +98.0% |
| FY2024 | $22.8M | +51.7% |
| FY2023 | $15.0M | +29.9% |
| FY2022 | $11.6M | +18.4% |
| FY2021 | $9.8M | +26.6% |
| FY2020 | $7.7M | -57.2% |
| FY2019 | $18.1M | -22.2% |
| FY2018 | $23.2M | +669.3% |
| FY2017 | $3.0M | -7.1% |
| FY2016 | $3.2M | -23.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026